Tazobactam
From Wikipedia, the free encyclopedia
| Image:TAZOBACTAM.png | |
| Tazobactam
| |
| Systematic (IUPAC) name | |
| (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-
(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid | |
| Identifiers | |
| CAS number | 89786-04-9 |
| ATC code | J01CG02 |
| PubChem | ? |
| DrugBank | EXPT03012 |
| Chemical data | |
| Formula | C10H12N4O5S1 |
| Mol. weight | 300.289 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tazobactam is a compound which inhibits the action of bacterial beta-lactamases. It is added to the extended spectrum beta-lactam antibiotic piperacillin to produce Tazocin® or Zosyn®. It broadens the spectrum of piperacillin by making it effective against organisms that express beta-lactamase and would normally degrade piperacillin.
Tazobactam sodium is a derivative of the penicillin nucleus and is a penicillanic acid sulfone.
